Related News
China's three biggest hepatitis B vaccine makers stop production
Online Edition
China's three biggest hepatitis B vaccine manufacturers have suspended production, the food and drug administration announced late on Thursday.
BioKangtai, Tiantan Biological Products and Dalian Hissen Bio-Pharm failed to meet the 2010 good manufacturing practice (GMP) code for all pharmaceutical manufacturers by the deadline at the end of 2013. Those who did not reach the new standards must suspend production in 2014.
Over the first 11 months last year, hepatitis B vaccines produced by the three suppliers accounted for about 80 percent of total output.
Hepatitis B vaccines sold in China are produced by seven companies, including British pharmaceutical company GlaxoSmithKline. Only two have passed the new GMP certification, responsible for no more than 10 percent of sales.
The statement by the China Food and Drug Administration (CDFA) says that companies may resume production after certification. Li Guoqing, a senior CFDA official, said vaccine supplies are sufficient to meet market demand.
The authority has clarified that vaccines produced before the deadline can still be sold. The five suspended manufacturers have inventories of qualified vaccines for about 25 inoculations, Li said.
The authority will organize increased production if necessary, the official said.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
